Every 10-Q that Cabaletta Bio, Inc. (CABA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CABA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CABA filings page.
Cabaletta Bio, Inc., a late-stage clinical biotechnology company developing engineered T cell therapies for autoimmune diseases, reported a Q2 2026 net loss of $51.0 million and a six‑month 2026 net loss of $94.5 million, driven mainly by research and development expenses of $81.8 million for the first half. Cash and cash equivalents increased to $225.1 million at June 30, 2026 from $83.0 million at year‑end 2025, primarily due to a May 2026 equity offering of 51.7 million shares at $2.90 per share and additional at‑the‑market sales. Total assets were $256.7 million with liabilities of $46.1 million and stockholders’ equity of $210.6 million. Management expects current cash to fund operations for at least 12 months but has identified conditions that raise substantial doubt about the ability to continue as a going concern without additional capital beyond the current runway. The company is advancing its lead CD19 CAR‑T candidate rese‑cel through multiple RESET Phase 1/2 and registrational cohorts in myositis, systemic sclerosis, lupus, myasthenia gravis and pemphigus vulgaris, supported by Fast Track, Orphan Drug, Rare Pediatric Disease and RMAT designations in several indications.
Cabaletta Bio reports wider quarterly losses as it advances its rese-cel autoimmune cell therapy program and faces funding risk. For the three months ended March 31, 2026, the company recorded a net loss of $43.5 million on operating expenses of $44.3 million, driven mainly by $37.4 million in research and development spending. Cash and cash equivalents were $116.6 million at quarter-end, and a May 2026 equity offering raised an additional $141 million in net proceeds. Management notes an accumulated deficit of $560.5 million and explicitly states that substantial doubt exists about the company’s ability to continue as a going concern, even though current resources are expected to fund operations for at least 12 months.
Cabaletta Bio reported a larger quarterly loss as it advanced its cell therapy programs and flagged liquidity risk. For the three months ended September 30, 2025, net loss was $44.9 million, compared with $30.6 million a year ago, driven by higher research and development spending of $39.8 million versus $26.3 million. General and administrative expense was $6.8 million, roughly flat year over year.
Cash, cash equivalents and short‑term investments totaled $159.9 million as of September 30, 2025. The company disclosed that substantial doubt exists about its ability to continue as a going concern, noting current cash, cash equivalents and investments may not fund operations for at least the next twelve months from issuance of the financial statements.
To bolster liquidity, Cabaletta closed a June 2025 financing, raising net proceeds of $93.6 million through common stock, pre‑funded warrants and common stock warrants. As of quarter‑end, 6,000,000 pre‑funded warrants remained outstanding; no common warrants had been exercised. The company also established a $150.0 million at‑the‑market program in August 2025. Voting common shares outstanding were 96,265,204 as of October 31, 2025.
Cabaletta Bio’s Q2-25 10-Q shows an enlarged pipeline but a materially higher cash burn. Operating expenses jumped 52% YoY to $45.9 M, driven by a 61% rise in R&D as the company advanced its CD19 CARTA program rese-cel across five autoimmune indications. The quarterly net loss widened to $45.1 M (-$0.73/sh) from $27.6 M (-$0.56/sh) one year ago; six-month loss reached $81.1 M.
Liquidity improved through an equity/warrant raise but a going-concern warning remains. In June the company issued 39.2 M shares plus 10.8 M pre-funded warrants, netting $93.6 M; an additional $2.6 M was raised via ATM sales. Cash & cash equivalents fell to $145.6 M but were supplemented by $49.1 M of new U.S. Treasury investments, lifting total cash & investments to $194.7 M. Lease-related assets boosted total assets to $224.5 M while finance lease liabilities rose to $20.3 M. Despite the capital infusion, management states that current resources “may not be sufficient” for 12 months, citing substantial doubt about going concern; cash burn from operations was $61.2 M in 1H-25.